Literature DB >> 20544842

MicroRNA-125b-1 and BLID upregulation resulting from a novel IGH translocation in childhood B-Cell precursor acute lymphoblastic leukemia.

Elisa Tassano1, Maura Acquila, Elisa Tavella, Concetta Micalizzi, Claudio Panarello, Cristina Morerio.   

Abstract

Chromosomal translocations involving the immunoglobulin heavy chain (IGH) locus are common abnormalities in mature B-cell neoplasms. Recent findings have also revealed their significant role in B-cell precursor acute lymphoblastic leukemia. As a rule, IGH translocations generate transcriptional activation of the oncogene localized in the proximity of the breakpoint. In this study, we describe a pediatric case of B-cell precursor acute lymphoblastic leukemia showing microRNA-125b-1 (MIR125B1) and BLID gene overexpression, resulting from a novel t(11;14)(q24.1;q32) translocation involving IGH. This is the first report describing the upregulation of a microRNA due to its juxtaposition to protein-coding gene regulatory elements and the overexpression of two neighboring genes as a consequence of transcriptional enhancers localized in the vicinity of the IGH gene.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20544842     DOI: 10.1002/gcc.20776

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  16 in total

1.  MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets.

Authors:  A G Lisa Ooi; Debashis Sahoo; Maddalena Adorno; Yulei Wang; Irving L Weissman; Christopher Y Park
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

2.  miRNA-convergent gene fusions.

Authors:  Carlos Rovira
Journal:  Mol Cell Oncol       Date:  2017-12-11

3.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

4.  MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.

Authors:  Yutaka Enomoto; Jiro Kitaura; Masaya Shimanuki; Naoko Kato; Koutarou Nishimura; Mariko Takahashi; Hideki Nakakuma; Toshio Kitamura; Takashi Sonoki
Journal:  Int J Hematol       Date:  2012-07-28       Impact factor: 2.490

5.  Dual mechanisms by which miR-125b represses IRF4 to induce myeloid and B-cell leukemias.

Authors:  Alex Yick-Lun So; Reeshelle Sookram; Aadel A Chaudhuri; Aarathi Minisandram; David Cheng; Catherine Xie; Ee Lyn Lim; Yvette Garcia Flores; Shuai Jiang; Jocelyn Tammy Kim; Christopher Keown; Parameswaran Ramakrishnan; David Baltimore
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

Review 6.  The Yin and Yang of microRNAs: leukemia and immunity.

Authors:  Alex Yick-Lun So; Jimmy L Zhao; David Baltimore
Journal:  Immunol Rev       Date:  2013-05       Impact factor: 12.988

7.  The Role of MicroRNAs in Hematopoietic Stem Cell and Leukemic Stem Cell Function.

Authors:  Stephen S Chung; Wenhuo Hu; Christopher Y Park
Journal:  Ther Adv Hematol       Date:  2011-10

8.  Aberrant BLID expression is associated with breast cancer progression.

Authors:  Xiaoyan Li; Peng Su; Xianqiang Liu; Xiangnan Kong; Xin Zhang; Hongyu Zhang; Qifeng Yang
Journal:  Tumour Biol       Date:  2014-02-15

9.  MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.

Authors:  U Knackmuss; S E Lindner; T Aneichyk; B Kotkamp; Z Knust; A Villunger; S Herzog
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

Review 10.  Diverse functions of miR-125 family in different cell contexts.

Authors:  Yu-Meng Sun; Kang-Yu Lin; Yue-Qin Chen
Journal:  J Hematol Oncol       Date:  2013-01-15       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.